Shariat SF - Search Results

1

What Is the Significance of Variant Histology in Urothelial Carcinoma?

Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM. Lobo N, et al. Among authors: shariat sf. Eur Urol Focus. 2020 Jul 15;6(4):653-663. doi: 10.1016/j.euf.2019.09.003. Epub 2019 Sep 15. Eur Urol Focus. 2020. PMID: 31530497 Review.

2

Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.

Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2000 Nov 1;56(5):735-40. doi: 10.1016/s0090-4295(00)00756-1. Urology. 2000. PMID: 11068290

3

E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.

Shariat SF, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2001 Jan;57(1):60-5. doi: 10.1016/s0090-4295(00)00892-x. Urology. 2001. PMID: 11164145

4

E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.

Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. Byrne RR, et al. Among authors: shariat sf. J Urol. 2001 May;165(5):1473-9. J Urol. 2001. PMID: 11342899

5

Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.

Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Andrews B, et al. Among authors: shariat sf. J Urol. 2002 Mar;167(3):1475-81. J Urol. 2002. PMID: 11832773

6

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.

Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Shariat SF, et al. J Urol. 2003 Mar;169(3):938-42. doi: 10.1097/01.ju.0000043638.89552.ed. J Urol. 2003. PMID: 12576817

7

Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.

Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Shariat SF, et al. Urology. 2003 May;61(5):1053-8. doi: 10.1016/s0090-4295(02)02522-0. Urology. 2003. PMID: 12736046

8

The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.

Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. Shariat SF, et al. J Urol. 2003 Dec;170(6 Pt 1):2244-7. doi: 10.1097/01.ju.0000090965.71697.37. J Urol. 2003. PMID: 14634389

9

Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.

Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Matsumoto K, et al. Among authors: shariat sf. J Urol. 2003 Dec;170(6 Pt 1):2248-52. doi: 10.1097/01.ju.0000094189.93805.17. J Urol. 2003. PMID: 14634390

10

Stage specific lymph node metastasis mapping in radical cystectomy specimens.

Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Vazina A, et al. Among authors: shariat sf. J Urol. 2004 May;171(5):1830-4. doi: 10.1097/01.ju.0000121604.58067.95. J Urol. 2004. PMID: 15076287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,824 results

Search Page